Table 3.
Significant odds ratios (95% CI) for all APOs and virus exposures*
| APO | Virus | Gestation (weeks) | Cases (positive/total) | OR (95% CI) | P value |
|---|---|---|---|---|---|
| PIHDs | Herpes PCR group B | All | 4/16 | 3.57 (1.10–11.57) | <0.05 |
| <37 | 4/12 | 5.35 (1.55–18.55) | <0.05 | ||
| <32 | 4/8 | 10.71 (2.58–44.42) | <0.01 | ||
| CMV | All | 13/23 | 3.89 (1.67–9.06) | <0.01 | |
| ≥37 | 5/6 | 14.97 (1.73–129.21) | <0.01 | ||
| <37 | 8/17 | 2.66 (1.00–7.02) | 0.05 | ||
| Herpes PCR group A | All | 13/23 | 3.27 (1.41–7.60) | <0.01 | |
| ≥37 | 5/6 | 12.58 (1.46–108.50) | <0.01 | ||
| Any herpesvirus | All | 14/18 | 5.70 (1.85–17.57) | <0.01 | |
| ≥37 | 5/5 | 17.89 (0.98–325.63) | <0.01 | ||
| <37 | 9/13 | 3.66 (1.11–12.06) | <0.05 | ||
| Any virus | All | 14/18 | 5.17 (1.68–15.94) | <0.01 | |
| ≥37 | 5/5 | 16.24 (0.89–295.57) | <0.05 | ||
| <37 | 9/13 | 3.33 (1.01–10.95) | <0.05 | ||
| APH + SGA | Herpes PCR group B | 32–36 | 6/29 | 2.79 (1.08–7.25) | <0.05 |
| PTB (non‐CP APO) | CMV | <37 | 82/247 | 1.61 (1.14–2.27) | <0.01 |
| 32–36 | 48/145 | 1.60 (1.06–2.42) | <0.05 | ||
| <32 | 34/102 | 1.62 (1.02–2.58) | <0.05 | ||
| Herpes PCR group A | <37 | 89/247 | 1.51 (1.08–2.10) | <0.05 | |
| 32–36 | 54/145 | 1.59 (1.07–2.36) | <0.05 | ||
| Any herpesvirus | <37 | 98/221 | 1.43 (1.02–2.01) | <0.05 | |
| 32–36 | 62/134 | 1.55 (1.04–2.30) | <0.05 | ||
| PTB + SGA (non‐CP APO) | Any herpesvirus | 32–36 | 16/29 | 2.21 (1.03–4.73) | <0.05 |
Positive, total number of samples testing positive for the viruses; total, total number of samples with a valid test result. Herpes PCR group B: VZV, HHV‐6, HHV‐7; Herpes PCR group A: HSV‐1, HSV‐2, EBV, CMV, HHV‐8; Any Herpesvirus: HSV‐1, HSV‐2, EBV, CMV, VZV, HHV‐6, HHV‐7, HHV‐8; Any Virus: any herpesvirus or enterovirus.
*
Not all samples had a valid test result for all viruses, therefore the total number of samples included in analyses may be less than the total number of cases and controls available for study.